Second line therapy for advanced pancreatic adenocarcinoma: Where are we and where are we going?

Journal of the Pancreas

Volumn 11, Issue 4, 2010, Pages 321-323

  Brus, Christina ^a   Saif, Muhammad Wasif ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

130 nm albumin bound paclitaxel; Capecitabine; Gemcitabine oxaliplatin regimen; Pancreatic neoplasms

Indexed keywords

ALBUMIN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; NANOPARTICLE; OSTEONECTIN; OXALIPLATIN; PACLITAXEL; SORAFENIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; STRATEGIC PLANNING; TREATMENT PLANNING; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; DISEASE COURSE; EVALUATION STUDY; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PANCREATIC NEOPLASMS; PROCEDURES; TRENDS; UNITED STATES;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHICAGO; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; DISEASE PROGRESSION; HUMANS; MEDICAL ONCOLOGY; PANCREATIC NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77954793384     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
3. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaneret I, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005; 23(16 Suppl):4031.
4. Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(15 Suppl):4508.
5. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481-5. [PMID 16434988]
6. Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76:333-7. [PMID 19307739]
7. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67:93-7. [PMID 15539911]
8. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658-63. [PMID 19826418]
9. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008: 113:2046-52. [PMID 18756532]
10. Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-8. [PMID 11081455]
11. Starling N, Hawkes EA, Chau I, Watkins DJ, Thomas J, Webb J, et al. A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). J Clin Oncol 2010; 28(15 Suppl):4155.
12. Lubner SJ, Schelman WR, Mulkerin D, Holen KD, Seo S, LoConte NK. Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4143.
13. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25:319-25. [PMID 17235047]
14. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol 2009; 27(15 Suppl):4525.
15. Hosein PJ, Lopes GD Jr., Gomez CM, Pastorini VH, Macintyre J, Easey M, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy. J Clin Oncol 2010; 28(15Suppl):4120.